To further study the collateral sensitivity of MDA-MB-231-BCRP cells to PT, we focused on NF-κB (Bork et al., 1997; Hayashi et al., 2010), which represents an important target for cancer therapy with more than 700 identified as NF-κB inhibitors, including PT (Gupta et al., 2010). The gene discussed is NFKB1; the disease is cancer.